

What other aging-associated musculoskeletal diseases (e.g., osteoporosis, sarcopenia, neurodegenerative, etc.) contribute to age-associated OA in animals?

Authors: Mingde Cao, Michael Tim-yun Ong, Wing-hoi, Cheung, Alan Zhong Li, Patrick Shu-Hang Yung

Response/Recommendation: Sarcopenia and osteoporosis contribute to osteoarthritis (OA) development in animal models. These conditions share overlapping pathophysiological mechanisms including mitochondrial dysfunction, altered mechano-transduction, and dysregulated musculoskeletal crosstalk mediated by myokines and osteokines, creating a cascade that accelerates joint degeneration.

Level Of Evidence: Moderate

Delegate Vote: Agree (TBD), Disagree (TBD), Abstain (TBD)

Rationale: Multiple aging-associated diseases, such as osteoporosis, sarcopenia, and neurodegenerative disorders, are considered to have a partial causal relationship with OA. Several Mendelian randomization studies have supported the casual relationship apart from the association¹⁻³. However, these findings should be interpreted with caution due to potential violations of MR assumptions. The aim of this review is to identify potential mechanisms by which osteoporosis, sarcopenia, and neurodegenerative diseases promote OA progression in animal models, thereby providing updated insights for the management of comorbidities collectively.

PubMed and Scopus were searched for potentially eligible studies from database inception to December 31, 2025. The search strategy included the following terms: “osteopor*” OR “sarcopeni*” OR “neurodegenerative disease” AND “osteoarthriti*” restricted to ti/ab. The initial literature search retrieved 4,576 records. After removing 536 duplicates, 3,724 studies were screened based on titles and abstracts. Subsequently, 156 studies underwent full-text review. Ultimately, 22 studies were included in the review⁴⁻²⁵.

Sarcopenia emerges as a critical contributor to OA pathogenesis through multiple mechanisms.

Sarcopenia is not merely a consequence of OA pain and immobility but an active contributor to joint degeneration⁴. In senescence accelerated mouse prone 8 (SAMP8) mice, a model of sarcopenia⁵, a more pronounced progression of OA can be observed compared with C57BL/6 mice without surgical induction⁶. However, the systemic accelerated aging inherent to the SAMP8 model may limit its suitability for elucidating the specific relationship between sarcopenia and OA. In rat MIA induced knee OA model, exercise-induced secretion of the myokine irisin was found to be chondroprotective⁷. Irisin is secreted primarily by muscle and could suppresses the NF-κB and MAPK signaling pathways in chondrocytes, downregulating MMP-13 and ADAMTS-5 while upregulating Type II collagen^{7, 8}. Intra-articular Irisin injection attenuated OA progression in DMM mice by restoring Sirt3 and UCP-1 signaling, improving mitochondrial function and antioxidant capacity⁹. The loss of muscle mass in aging leads to reduced systemic irisin, removing this "brake" on catabolic enzymes and decreasing mitochondrial biogenesis. In a mouse ACL rupture model, although it is not a classic sarcopenia model, unresolved muscle weakness and post-traumatic osteoarthritis are present. Modulating GDF8/myostatin, an endogenous muscle inhibitory factors can promote recovery of muscle function and partially prevent PTOA¹⁰. Notably, GDF8 has also been identified as a key negative regulator of muscle mass in postmenopausal females¹¹.

Osteoporosis-OA represents a particularly detrimental combination.

Osteoporosis may directly contribute to OA by altering subchondral bone structure and remodeling in ways that exacerbate cartilage damage. In a female rabbit model, OVX-induced osteoporosis followed by ACLT resulted in greater cartilage damage compared with controls¹². Likewise, in rats with medial meniscectomy induced knee OA, superimposed OVX-induced osteoporosis causes higher subchondral bone damage scores, more porous trabecular bone, and greater subchondral osteoclast density and aggravated OA pathology¹³. The weakened and highly remodeled subchondral bone, characterized by a low OPG/RANKL ratio and increased MMP9 expression, transmits abnormal mechanical stress and biochemical signals to the cartilage, accelerating cartilage degeneration and worsening OA^{12, 14}. In addition, in female mice (26 weeks old) with osteopenic subchondral bone (SCB plate thickness, BMD, BV/TV↓) caused by osteoblast-specific estrogen receptor- α knockout (pOC-ER α KO), mechanical loading induces more severe cartilage damage and worse histologic OA scores than in littermate controls¹⁵.

Bone-derived factors, or osteokines, which change in response to aging and mechanical loading, may represent another key class of mediators¹⁶. Osteoblasts, the primary bone-forming cells, are now recognized as mature endocrine cells. Several osteokines, including Tgfb β , osteonectin (Sparc), and osteopontin (SPP1), have been reported to be closely associated with the progression of OA¹⁷⁻¹⁹.

Neurodegenerative disease and OA link is not clear

The relationship between OA and neurodegenerative diseases, including Alzheimer's disease (AD) and Parkinson's disease (PD), remains incompletely understood²⁰. Although chronic inflammation and oxidative stress—hallmarks of OA—are known contributors to neurodegeneration, current epidemiological and clinical evidence linking OA to AD or PD is largely correlational²¹. As a result, whether OA and neurodegenerative disease risk are mutually contributory remains unresolved.

Several studies suggest that OA pathology may exacerbate neurodegenerative processes. DMM-induced OA significantly increased pro-inflammatory cytokine expression in the brains of 5xFAD mice and accelerated A β plaque deposition and neuronal loss compared to sham control²². Similarly, in the APP/PS1; Col1-IL1 β ^{XAT} compound transgenic mice, induction of OA exacerbated and accelerated neuroinflammation, as evidenced by increased glial activation and worsened A β pathology²³. However, a limitation of these studies is that it did not assess whether AD mice themselves develop a more severe OA phenotype than WT controls.

Recent study further highlights the coupling between brain health and musculoskeletal homeostasis. A study demonstrated that aged neurons in the hippocampus and cerebral cortex produce elevated levels of WDFY1, which is transferred to bone via extracellular vesicles (EVs) and induce osteoporosis²⁴. This finding suggests that the nervous system may influence cartilage health through paracrine signaling. In addition, neurodegeneration and aging—particularly of sensory neurons—are associated with chronic OA pain. 20-Mo male mouse DRGs showed increased expression of *Ccl2* and *Ccl5*, and 20-Mo female mouse DRGs showed increased *Cxcr4* and *Ccl3* expression compared to 6-month-old mouse DRGs, with overall more severe pain-related behaviors than in young mice²⁵.

Reference

1. Qu Y, Chen S, Han M, Gu Z, Zhang Y, Fan T, et al. Osteoporosis and osteoarthritis: a bi-directional Mendelian randomization study. *Arthritis research & therapy*. 2023;25(1):242.
2. Yang J, Liu P, Wang S, Jiang T, Zhang Y, Liu W. Causal relationship between sarcopenia and osteoarthritis: a bi-directional two-sample mendelian randomized study. *European journal of medical research*. 2023;28(1):327.
3. Cai Y, Zhang G, Liang J, Jing Z, Zhang R, Lv L, et al. Causal relationships between osteoarthritis and senile central nerve system dysfunction: A bidirectional two-sample mendelian randomization study. *Frontiers in Aging Neuroscience*. 2022;13:793023.
4. Mao X, Lv K, Qi W, Cheng W, Li T, Sun Y, et al. Research progress on sarcopenia in the musculoskeletal system. *Bone Research*. 2025;13(1):78.
5. Zhang N, Chow SKH, Leung KS, Lee HH, Cheung WH. An animal model of co-existing sarcopenia and osteoporotic fracture in senescence accelerated mouse prone 8 (SAMP8). *Exp Gerontol*. 2017 Oct 15;97:1-8. Epub 20170712.
6. Sanada Y, Ikuta Y, Ding C, Shinohara M, Yimiti D, Ishitobi H, et al. Senescence-accelerated mice prone 8 (SAMP8) in male as a spontaneous osteoarthritis model. *Arthritis Research & Therapy*. 2022;24(1):235.
7. Duan Z, Gao H, Xiao X, He B. Comparison of passive and active motion: effect of myokine irisin on cartilage in knee osteoarthritis rats. *Frontiers in Physiology*. 2025;16:1639174.
8. Roggio F, Petrigna L, Trovato B, Di Rosa M, Musumeci G. The role of lubricin, irisin and exercise in the prevention and treatment of osteoarthritis. *International journal of molecular sciences*. 2023;24(6):5126.
9. Wang F-S, Kuo C-W, Ko J-Y, Chen Y-S, Wang S-Y, Ke H-J, et al. Irisin mitigates oxidative stress, chondrocyte dysfunction and osteoarthritis development through regulating mitochondrial integrity and autophagy. *Antioxidants*. 2020;9(9):810.
10. Brightwell CR, Latham CM, Keeble AR, Thomas NT, Owen AM, Reeves KA, et al. GDF8 inhibition enhances musculoskeletal recovery and mitigates posttraumatic osteoarthritis following joint injury. *Science Advances*. 2023;9(48):eadi9134.
11. Gonzalez Trotter D, Donahue S, Wynne C, Ali S, Parasoglou P, Boyapati A, et al. GDF8 and activin A are the key negative regulators of muscle mass in postmenopausal females: a randomized phase I trial. *Nature Communications*. 2025;16(1):4376.
12. Bellido M, Lugo L, Roman-Blas JA, Castañeda S, Caeiro JR, Dapia S, et al. Subchondral bone microstructural damage by increased remodelling aggravates experimental osteoarthritis preceded by osteoporosis. *Arthritis research & therapy*. 2010;12(4):R152.
13. Wada H, Aso K, Izumi M, Ikeuchi M. The effect of postmenopausal osteoporosis on subchondral bone pathology in a rat model of knee osteoarthritis. *Scientific Reports*. 2023;13(1):2926.
14. Bellido M, Lugo L, Roman-Blas JA, Castañeda S, Caeiro JR, Dapia S, et al. Subchondral bone microstructural damage by increased remodelling aggravates experimental osteoarthritis preceded by osteoporosis. *Arthritis Res Ther*. 2010;12(4):R152. Epub 20100802.
15. Ziemian SN, Ayobami OO, Rooney AM, Kelly NH, Holyoak DT, Ross FP, et al. Low bone mass resulting from impaired estrogen signaling in bone increases severity of load-induced osteoarthritis in female mice. *Bone*. 2021;152:116071.
16. Liang W, Wei T, Hu L, Chen M, Tong L, Zhou W, et al. An integrated multi-omics analysis

reveals osteokines involved in global regulation. *Cell metabolism*. 2024;36(5):1144-63. e7.

17. Qu Y, Li S, Luo H, Li J, Wang T, Han X. The Crucial Role of SPP1 in Osteoporosis, Osteoarthritis, and Cancer. *Pharmaceutical Science Advances*. 2025:100074.

18. Jiang A, Xu P, Yang Z, Zhao Z, Tan Q, Li W, et al. Increased Sparc release from subchondral osteoblasts promotes articular chondrocyte degeneration under estrogen withdrawal. *Osteoarthritis and Cartilage*. 2023;31(1):26-38.

19. Ruiz M, Toupet K, Maumus M, Rozier P, Jorgensen C, Noël D. TGFBI secreted by mesenchymal stromal cells ameliorates osteoarthritis and is detected in extracellular vesicles. *Biomaterials*. 2020;226:119544.

20. Prasoon P, Nguyen KL, Fathi PA, Gupta S, Arnab S, Jones E, et al. Pathophysiological mechanisms linking osteoarthritis and neurodegenerative disease risk. *Osteoarthritis and Cartilage*. 2025.

21. Rabie MA, Madry H, Cucchiari M, El-Sayed NS. The brain-joint axis: links between osteoarthritis and neurodegenerative disorders in aging. *Journal of Advanced Research*. 2025.

22. Gupta DP, Lee Y-S, Choe Y, Kim K-T, Song GJ, Hwang S-C. Knee osteoarthritis accelerates amyloid beta deposition and neurodegeneration in a mouse model of Alzheimer's disease. *Molecular Brain*. 2023;16(1):1.

23. Kyrkanides S, Tallents RH, Miller J-nH, Olschowka ME, Johnson R, Yang M, et al. Osteoarthritis accelerates and exacerbates Alzheimer's disease pathology in mice. *Journal of neuroinflammation*. 2011;8(1):112.

24. Chen C-Y, Wang Z, Hong C-G, Tan Y-J, Duan Y-X, Luo Y, et al. Brain neuron-derived WDFY1 induces bone loss. *Nature Aging*. 2026:1-20.

25. Geraghty T, Obeidat AM, Ishihara S, Wood MJ, Li J, Lopes EBP, et al. Age-associated changes in knee osteoarthritis, pain-related behaviors, and dorsal root ganglia immunophenotyping of male and female mice. *Arthritis & Rheumatology*. 2023;75(10):1770-80.